Amryt Pharma Share Discussion Threads

[papillon] 23/11/2018 15:32

mdalos1 23 Nov '18 - 14:46 - 3704 of 3704 (Filtered)

You can't view MADlosses previous posts on AMYT on advfn because the cunning stunt deletes them soon after posting. However his first post on advfn was back on the 5th May this year, the same date he joined advfn (of course he probably didn't join advfn on that date; it's probably just another of his aliases).

Here's my posts in reply to his post. You can then get the flavour of his first post. He's lying about the subsiduaries "creaming" off the profits from Lojuxta. It's just as well he's deleted his post because if you sent it AMYT they wouldn't be too happy because it's tantamount to accusing them of fraud! MADloss has been conducting a vendetta against AMYT by telling lies and spreading FAKE news. Why? I don't know! Make up your own mind

papillon 5 May '18 - 22:36 - 2760 of 3704 Edit
0 1 0
We're honoured, mdalos. You joined advfn on Thursday and your first post is on AMYT! Your name's not Alan Harris by any chance? LOL. Only joking (I think!). :-)

You make some valid points, mdalos. I to noticed that revenue was 12.778m Euro's for 2017, whilst cost of sales was 5.373m Euro's leaving a gross profit of 7.405m Euro's. Of course that profit disappears and turns into a 3.078m Euro's loss when Admin, selling and marketing expenses of 10.483m Euro's are taken into account! It doesn't sound good, but I think one has to take into account the fact that AMYT has had to set up a marketing and sales organisation from scratch to sell Lojuxta. That costs money. Probably some of those initial start up costs wont be repeated. The important thing is now that AMYT have set up a marketing & sales organisation those costs shouldn't increase significantly when (and if) AMYT complete another Lojuxta type licensing deal.

"What do all those subsidiaries do... who "owns" them and actually benefits from Funds channelled through them ?" What subsiduaries are you talking about, mdalos? Could you please elucidate? I don't see any mentioned in the final results RNS dated 17/4/2018 apart from the vehicles, such as Amyrt DAC & Amyrt AG, set up to facilitate the RTO..

papillon 6 May '18 - 10:01 - 2763 of 3704 Edit
0 2 0
It's worth remembering, mdalos, that the way the AMYT a/c's are set out is not unusual (in fact it's the norm!). Have a look at how other AIM listed companies with a revenue stream set out their a/c's if you don't believe me.

AMYT have separately detailed the direct cost of selling Lojuxta (5.373m Euro's) and then recorded separately the Admin, Sales & Marketing costs NOT solely related to the selling of Lojuxta. Don't forget a large chunk of those 10.483m Euro's is related to the admin of AMYT. Look at the AMYT web site and see have many senior execs that AMYT employ. These execs will be on large salaries and, no boubt, have a fully staffed office supporting them. A poster who used to post on here used to call it "snouts in the trough" and I understand his comments, but AMYT is going down a different route to, say N4P, where they are "outsourcing" many of the functions that AMYT are keeping "in house", so these AMYT admin costs are, no doubt, unavoidable.

Also the sales & marketing costs in that 10.483m Euro's are NOT solely directed at selling Lojuxta. In fact, as the company states, they are gearing up their sales & marketing organisation primarily to sell Episalvan (if it passes phase III and receives regulatory approval as a treatment for EB). AMYT are also gearing up to manufacture Episalvan. Also AMYT expect to secure more Lojuxta type licensing deals in the future so a sales & marketing organisation not solely linked to selling Lojuxta is essential.

papillon 6 May '18 - 13:36 - 2765 of 3704 Edit
0 3 0
You are correct, JimbobTechstock & Bermudashorts. I think mdalos is engaging in a bit of clever disinformation, for whatever reason. There are NO subsiduaries "channelling" the profits away! I've read the audited final results for 2018 yet again and can find NO evidence to back up mdalos's claim. Also the way the a/c's are set out; cost of sales for Lojuxta (and Imlan) and a separate cost for admin, sales & marketing for AMYT NOT directly linked to the sale of Lojuxta (and Imlan) is NOT unusual; in fact it's the norm for such a company as AMYT with just one revenue stream (mostly Lojuxta sales plus a small contribution from Imlan).

I respect someone with a different opinion of AMYT to me, even if it's a very negative opinion, but what I can't stand is someone making statements, without even a shred of evidence, that are obviously lies to back up their opinion. mdalos is, unfortunately, LYING when he states AMYT are "channelling" profits away to subsiduaries!

I suspect (though obviously can't prove) that mdalos did NOT join advfn last Thursday as his profile states. Rather I believe he's a long term member of advfn, but with numerous aliases. Unfortunately it is so easy to create numerous aliases on advfn; not so on the lse bb's. I think JimbobTechstock is correct and that mdalos has an ulterior motive behind his lies. I wonder if we will hear from him again?

greendragon777 6 May '18 - 14:16 - 2766 of 3704
0 2 0
Nothing gets past Detective Paps around here! 😀

[bermudashorts] 23/11/2018 13:43

Link below is to podcast of new Pharmaphorum interview with Joe Wiley

[papillon] 22/11/2018 23:38

But I'm talking about a key support level being breached in early September almost 6 MONTHS AFTER the delay to the reporting of the EASE trial interim analysis was announced in mid March, greendragon.

I thinking of having one final, small, £500 top up tomorrow morning. In for a penny, in for a pound. There's one born every minute! :-) Fingers crossed.

[greendragon777] 22/11/2018 22:23

In fairness Paps, the delay to the EASE trials was out of left field so the charts wouldn't have been much use for that. It's all about the interims now and any other deals that may crop up.

It's a mugs game trying to catch the bottom of any stock or market. As the saying goes...."anyone who tries to pick bottoms get brown fingers!" 😁

[papillon] 22/11/2018 21:58

I hope so, greendragon. However I'm kicking myself for NOT selling all my shares when that 17.3p failed to act as support and buying back a lot cheaper, especially as I knew news was not due until December. For a chap who says he studies charts & chart indicators that was inexcusable. I've also added since then without knowing for sure what I considered to be the bottom. I think we have hit rock bottom now in the lead up to the EASE interim analysis. What happens after that news is released? FINGERS CROSSED it's good news! I'm happy to gamble my circa £5k, though if I was buying for the first time now I'd get a lot more shares than 30k for my £5k stake. After all I don't believe AMYT to be yet another AIM fantasy, or fraud. Also I believe the odds on good news next month is greater than 50%. FINGERS CROSSED!

[greendragon777] 22/11/2018 21:19

I think it'd share price will smash through 17p on good news in December Paps, I would be shocked if it didn't. We can start counting down the days from here so brace yourself.....for a wonderful Christmas! 😁

[papillon] 22/11/2018 20:24

Only 7 trades today, greendragon. The first was a small 10k sell. The next 6 trades were all buys, but all very small. None over 5k.

The direction of the share price after the EASE interim analysis? Who knows? Hopefully it's up. As I've always said I've got my fingers crossed we get good news. Again, as I've always said I've added to my original FAST holding by buying some extra AMYT shares because of the EASE Phase III trial result. I need a 25% rise in the AMYT share price to breakeven.

If you visit investtech.com they don't have a support level for the AMYT share price The last support level @ 17.3p was breached almost 3 months ago. That 17.3p now becomes a chart resistance level. investtech.com also show another chart resistance level at 20p. I'm currently down circa 25% on my 30k of AMYT. The AMYT share price would need to rise by circa 40% to get back to 17.3p so that would put me back into profit.

I didn't expect that 17.3p support level to be broken. Will it be breached when that 17.3p acts as a resistance level? I sincerely hope so. However I haven't got a crystal ball. I can't predict share prices just as I can't predict what will be in December's RNS. All I can do is hope for good news and a significantly higher share price As I've posted many times before I consider AMYT to be a good gamble on the EASE Phase III trial result. A gamble I'm happy to take.

[papillon] 22/11/2018 18:39

I see MADloss has been busy. 5 posts in quick succession! ALL FILTERED!

"and Scioderm just had Zorblisa in their portfolio?" You tell me digadee. All the future payments are linked to the progress of Zorblisa, so if Scioderm did have anything else worthwhile "in their portfolio" it would seem Amicus weren't interested in it!

[greendragon777] 22/11/2018 17:18

3 weeks from tomorrow Paps and things will look very different from where we are at right now.....hopefully a dramatically higher share price too as a result!

Tick tock tick tock......

[digadee] 22/11/2018 16:27

and Scioderm just had Zorblisa in their portfolio?

[papillon] 22/11/2018 15:28

>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>

Talk about being sold a pup, or buying a pig in a poke! And I thought I'd made a big mistake buying 30k of AMYT/FAST shares far too early! LOL

."The Transaction

Amicus will acquire Scioderm in a cash and stock transaction. At closing, Amicus will pay Scioderm shareholders $229 million, of which $125 million will be paid in cash and $104 million will be paid through the issuance of 7 million newly issued Amicus shares. Amicus has agreed to pay up to an additional $361 million to Scioderm shareholders in cash or stock upon achievement of certain clinical and regulatory milestones and $257 million to Scioderm shareholders in cash or stock upon achievement of certain sales milestones. If Zorblisa is approved, EB qualifies as a rare pediatric disease and a Priority Review Voucher will be requested. If the Priority Review voucher is obtained and subsequently sold, Amicus will pay Scioderm shareholders the lesser of $100 million or 50% of the proceeds of such sale. The transaction is subject to customary conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The Boards of both companies have approved the transaction and the companies currently anticipate that the transaction will be completed in the third quarter of 2015."

[papillon] 22/11/2018 12:36

Looking at the AMYT chart (pass the sick bag, Alice!), greendragon, I expect the AMYT share price to continue to move sideways and hence the Bollingers Bands to narrow as we get closer to the EASE interim analysis RNS. Then the direction of the AMYT share price is in the lap of the Gods and will depend of the contents of that RNS.

PS. The moral of this AMYT saga as far as I'm concerned is NEVER ignore what the chart is telling you! As I've posted many times before the chart said sell over a year ago and it hasn't said buy to me since then.

Of course if one wanted to have a punt on the outcome of the EASE trial (and I do!) then now is the time, IMO, because I don't forsee the share price moving much from it's current position before that interim analysis RNS. I got involved far too early. With the benefit of hindsight I should have sold back in March following that RNS announcing the postponement of the EASE interim analysis and bought back now at a far cheaper price since the EASE trial was my prime reason for investing in AMYT in the first place. Ah, such is life. It's very hard to teach an old dog new tricks, greendragon.

[papillon] 22/11/2018 11:47

It's definitely painful for me to look at the AMYT chart, greendragon! I feel sick every time I look at it! :-)

[greendragon777] 20/11/2018 22:36

Can't disagree with him Paps........it's finally crashing and the question now is will any Cryptos emerge from the rubble over the next few years? I honestly can't see Blockchain technology going away but we'll see. The speculation seems to well and truly over......over $700bn evaporated into thin air, a lot of punters in pain....a bit like us with AMYT, but not for much longer hopefully! 😁😉

[papillon] 20/11/2018 11:58

O/T. Cryptocurrencies are doomed, greendragon. So says the man, Nouriel Roubini, who almost alone amongst economists predicted the credit crunch of 10 years ago and it's dire consequences.

[greendragon777] 19/11/2018 22:20

Seems to be falling off a cliff Paps. I guess my remaining stash is a write off at this stage but I'll hold them anyway!

Markets getting a bit jittery again today just when it looked like they were settling down. The quicker mid December comes now the better......we've got some Christmas shopping to do! 😁

[papillon] 19/11/2018 15:03

O/T. Cryptocurrencies being hammered again today, greendragon, especially IOTA. You did well by selling too early.